Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Talis Biomedical Corp (TLIS)

Talis Biomedical Corp (TLIS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 16,398
  • Shares Outstanding, K 1,822
  • Annual Sales, $ 2,130 K
  • Annual Income, $ -62,010 K
  • 60-Month Beta 1.74
  • Price/Sales 7.86
  • Price/Cash Flow N/A
  • Price/Book 0.24
Trade TLIS with:

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.50 +20.00%
on 04/03/24
9.20 -2.18%
on 04/24/24
+0.10 (+1.13%)
since 03/25/24
3-Month
7.01 +28.39%
on 02/07/24
9.32 -3.43%
on 03/18/24
+0.93 (+11.52%)
since 01/25/24
52-Week
4.35 +106.90%
on 10/31/23
9.32 -3.43%
on 03/18/24
+1.52 (+20.29%)
since 04/25/23

Most Recent Stories

More News
Amicus Therapeutics (FOLD) Reports Q1 Loss, Tops Revenue Estimates

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -38.46% and 5.03%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

FOLD : 10.26 (+0.88%)
TLIS : 9.00 (-2.18%)
Halozyme Therapeutics (HALO) Q1 Earnings and Revenues Miss Estimates

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of -2.08% and 6.92%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

HALO : 38.70 (+0.62%)
TLIS : 9.00 (-2.18%)
Talis Biomedical Corporation (TLIS) Stockholders: Robbins LLP is Investigating TLIS on Behalf of Shareholders

Shareholder rights law firm Robbins LLP is investigating Talis Biomedical Corporation (NASDAQ: TLIS) to determine whether certain Talis officers and directors violated securities laws and breached fiduciary...

TLIS : 9.00 (-2.18%)
Talis Biomedical Provides Business Update and Reports Second Quarter Financial Results

Conference call and webcast today at 4:30pm Eastern/1:30pm Pacific...

TLIS : 9.00 (-2.18%)
Talis Biomedical Corporation (TLIS) Q1 2022 Earnings Call Transcript

TLIS earnings call for the period ending March 31, 2022.

TLIS : 9.00 (-2.18%)
Clene Inc. (CLNN) Reports Q1 Loss, Lags Revenue Estimates

Clene Inc. (CLNN) delivered earnings and revenue surprises of -16.67% and 76%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

CLNN : 0.3465 (unch)
TLIS : 9.00 (-2.18%)
MannKind (MNKD) Reports Q1 Loss, Tops Revenue Estimates

MannKind (MNKD) delivered earnings and revenue surprises of 0% and 14.91%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

MNKD : 4.32 (+3.35%)
TLIS : 9.00 (-2.18%)
Talis Biomedical to Announce First Quarter 2022 Financial Results on May 10, 2022

MENLO PARK, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation ("TLIS"), a company dedicated to advancing health equity and outcomes...

TLIS : 9.00 (-2.18%)
Talis Biomedical Corporation (TLIS) Q4 2021 Earnings Call Transcript

TLIS earnings call for the period ending December 31, 2021.

TLIS : 9.00 (-2.18%)
Talis Biomedical Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

Conference call and webcast today at 4:30pm Eastern/1:30pm Pacific...

TLIS : 9.00 (-2.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Talis Biomedical Corporation engaged in developing and commercializing products for infectious diseases at the point-of-care. The company involved in developing the Talis One platform, a compact, sample-to-answer, cloud-enabled, molecular diagnostic platform. Talis Biomedical Corporation is based in...

See More

Key Turning Points

3rd Resistance Point 9.58
2nd Resistance Point 9.31
1st Resistance Point 9.15
Last Price 9.00
1st Support Level 8.72
2nd Support Level 8.45
3rd Support Level 8.29

See More

52-Week High 9.32
Last Price 9.00
Fibonacci 61.8% 7.42
Fibonacci 50% 6.84
Fibonacci 38.2% 6.25
52-Week Low 4.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar